Actively Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Led by Janssen Research & Development, LLC · Updated on 2026-05-08
140
Participants Needed
14
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).
CONDITIONS
Official Title
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria
- Meet treatment regimen-specific requirements based on prior therapies or newly diagnosed status
- Have a weight of 40 kilograms or more
- Have an Eastern Cooperative Oncology Group status of 0 or 2
- Have measurable disease at screening defined by serum or urine monoclonal protein levels, free light chain levels, or extramedullary disease meeting specific imaging criteria
You will not qualify if you...
- Have serious medical conditions such as active infections needing treatment, active autoimmune disease requiring recent immunosuppressive therapy, or significant heart conditions within the last 6 months
- Received certain prior antitumor therapies within specified time frames before study treatment, including targeted therapy, monoclonal antibodies, gene-modified cell therapy, chemotherapy, proteasome inhibitor or immunomodulatory therapies, and radiotherapy
- Had stem cell transplantation recently, including allogeneic transplant within 6 months or autologous transplant within 12 weeks before starting study treatment
- Have unresolved nonhematologic toxicities from prior anticancer therapy except specific exceptions
- Prior treatment with CD3-redirecting therapy
- Have medical conditions like pulmonary compromise requiring oxygen, HIV infection, active hepatitis B or C, or recent stroke or seizure within 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Monash Medical Centre
Clayton, Australia, 3168
Actively Recruiting
2
St Vincents Hospital Melbourne
Fitzroy, Australia, 3065
Actively Recruiting
3
Peter MacCallum Cancer Centre
Melbourne, Australia, 3000
Actively Recruiting
4
Calvary Mater Newcastle Hospital
Waratah, Australia, 2298
Actively Recruiting
5
Wollongong Hospital
Wollongong, Australia, 2500
Actively Recruiting
6
Carmel Medical Center
Haifa, Israel, 3436212
Actively Recruiting
7
Hadassah Medical Center
Jerusalem, Israel, 9112001
Actively Recruiting
8
Sheba Medical Center
Ramat Gan, Israel, 52621
Actively Recruiting
9
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239
Actively Recruiting
10
VU Medisch Centrum
Amsterdam, Netherlands, 1081 HV
Actively Recruiting
11
Universitair Medisch Centrum Groningen
Groningen, Netherlands, 9713 GZ
Actively Recruiting
12
UMC Utrecht
Utrecht, Netherlands, 3584 CX
Actively Recruiting
13
Hosp. Clinic de Barcelona
Barcelona, Spain, 08036
Actively Recruiting
14
Hosp Clinico Univ de Salamanca
Salamanca, Spain, 37007
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here